Whalesbook
Transgene Biotek Faces Financial Collapse Amidst SEBI Freeze and Deepening Losses
Mumbai: Transgene Biotek Limited has reported a grim financial picture for the third quarter and the first nine months of FY26, marked by a significant surge in net losses and a sharp decline in revenue. Compounding these dire financial results, the company's operations are currently at a standstill due to a prohibitory order from the Securities and Exchange Board of India (SEBI) freezing its bank accounts and assets.
Financial Deep Dive
The Numbers:
For the quarter ended December 31, 2025 (Q3 FY26), Transgene Biotek reported consolidated revenue from operations of ₹5.45 Lakhs, a steep 28.76% decrease compared to ₹7.65 Lakhs in the same period last year (Q3 FY25). The company posted a net loss of ₹37.38 Lakhs (₹0.37 Cr) for Q3 FY26, a significant jump from the ₹8.90 Lakhs (₹0.09 Cr) net loss in Q3 FY25.
Looking at the nine-month period ended December 31, 2025 (9M FY26), revenue from operations stood at ₹15.68 Lakhs, down 15.42% from ₹18.42 Lakhs in 9M FY25. The company swung from a net profit of ₹3.70 Lakhs (₹0.04 Cr) in 9M FY25 to a substantial net loss of ₹119.59 Lakhs (₹1.20 Cr) in 9M FY26.
The Quality:
The financial deterioration is driven by a significant increase in total expenses, which more than doubled in Q3 FY26 YoY and rose by over 50% in 9M FY26. Notably, finance costs have soared, amounting to ₹78.33 Lakhs in 9M FY26, far exceeding the operational revenue generated. A critical factor contributing to the increased losses is the complete absence of 'Other Income' in the current fiscal year's results, whereas the previous year's nine-month period benefited from ₹73.96 Lakhs in such income.
Adding to the financial strain is a massive contingent liability of ₹408.74 Crores as per the latest available balance sheet data. The company's debt-to-equity ratio has also remained high, indicating a leveraged financial structure.
Backstory & Red Flags
The Troubled Past:
Transgene Biotek has a long and troubled history with regulatory bodies. As far back as 2014, SEBI initiated investigations into allegations of fraud concerning the company's issuance of Global Depository Receipts (GDRs) and subsequent misuse of funds [5, 11, 20]. These investigations led to SEBI barring the company's promoters and directors from accessing capital markets in an interim order [11].
Operational Paralysis:
More recently, Transgene Biotek disclosed on February 3, 2026, that SEBI's Recovery Officer had issued a prohibitory order freezing all company bank accounts and prohibiting the disposal of assets. This action is in pursuit of an unpaid penalty of ₹38 Lakhs from a June 27, 2022, adjudication order [8, 9]. The company stated that these recovery proceedings have brought all business activities, including salary payments, to a complete standstill, causing operational paralysis [9]. Adding to this, the company faces a significantly larger penalty of ₹203.02 Crores from the Enforcement Directorate related to its GDR scheme [7].
Ongoing Legal Battles:
The company is actively involved in several legal proceedings. Updates on matters before the Securities Appellate Tribunal (SAT), the Appellate Tribunal in New Delhi, and the National Company Law Tribunal (NCLT) Hyderabad bench were provided, with next hearing dates ranging from late February to April 2026 [8].
Risks & Outlook
Specific Risks:
- Performance Risk: Continued revenue decline and widening net losses pose a severe threat to the company's viability.
- Financial Risk: Extremely high finance costs, a heavy debt burden (high debt-to-equity ratio), and a massive contingent liability create significant financial distress. The freezing of bank accounts exacerbates liquidity concerns.
- Regulatory and Governance Risk: The ongoing SEBI actions, historical fraud allegations, and pending legal cases present substantial governance and compliance risks. The operational paralysis is a direct consequence of regulatory enforcement.
The Forward View:
No future guidance was provided by the management. Investors will be closely watching the progress of the SAT appeal against the SEBI penalty, the resolution of the Enforcement Directorate's larger penalty, and any steps the company takes to stabilize its operations and finances. However, the current situation suggests an extremely challenging road ahead.
Peer Comparison
Transgene Biotek's dismal performance stands in stark contrast to the broader Indian pharmaceutical and biotechnology sector, which is generally experiencing growth [6, 10]. Major players like Biocon reported strong revenue growth and healthy EBITDA margins for Q3 FY26 [18]. Even competitors like Panacea Biotec, while facing some challenges, are profitable and have significantly larger market capitalizations [12]. Transgene Biotek's struggles highlight its unique and severe operational and financial distress within an otherwise resilient industry.